GlaxoSmithKline Pharmaceuticals Limited CC-Dec24.pdf · 2025-02-14
Yes. So, congratulations on a great set of numbers. See, I have a question around GenMed. So, our volume growth for the quarter was around 11% and nine months would be around 9 -10%. So, have you taken any price hike in this segment or is there any element of pricing impact for the quarter and nine months in the GenMed segment?
And see, the employee cost for the quarter was lower by around 25 crores right now. How should we look at employee cost going forward? Is this the base or was there any sort of one-off?